Molecular Formula | C14H10BNO3 |
Molar Mass | 251.05 |
Density | 1.33±0.1 g/cm3(Predicted) |
Boling Point | 425.9±55.0 °C(Predicted) |
Storage Condition | -20℃ |
Physical and Chemical Properties | Storage: room temprature. powder. Color: white to beige |
Use | Briborol (AN2728) is a non-steroidal phosphodiesterase 4(PDE-4) inhibitor. It was first developed by AnacorPharmaceuticals and acquired by Anacor in May 2016. In December of the same year, the US FDA approved the marketing of kliboruo (AN2728) Ointment (2% or 5%), for topical treatment of mild to moderate atopic dermatitis in patients over 2 years of age under the trade name Eucrisa. |
erioborro was developed by Anacor company, and Pfizer company acquired Anacor company at a high price, it is the first new molecular entity approved by the US FDA for the treatment of atopic dermatitis (AD) in the past 15 years. 7/20/2017, clicaborol ointment was approved for marketing in China, become the first and only topical prescription drug of hormone-free PDE-4 inhibitor in China for the treatment of mild to moderate atopic dermatitis in children and adults aged 2 years and over. Crestor is a phosphodiesterase 4(PDE4) inhibitor, PDE4 is an enzyme involved in the control of inflammatory cell activity, PDE4 by controlling the degradation of cyclic adenosine monophosphate, it is involved in the production of inflammatory factors such as IL-4/10/13 and prostaglandin PGE2 in inflammatory cells, and plays a role in improving the body's inflammatory response by inhibiting PDE4 activity. Clinical studies have shown that in patients 2-79 years of age with mild-to-moderate atopic dermatitis, treatment with briborol for 28 days resulted in significant remission of the patient's condition, complete or almost complete resolution of the rash, compared to placebo. Clenborol had sales of US $67 million in and global sales of US $0.147 billion in 2018, with a growth rate of 119.40%, bringing new hope to many patients with atopic dermatitis.
AN2728 shows potent activity both in vitro and in vivo, and the anti-inflammatory properties of AN2728 are being investigated. It is also used as a pharmaceutical intermediate.
Crisaborole (AN2728) is a selective small molecule PDE4 inhibitor with a broad spectrum of anti-inflammatory activity.
The biggest advantage of clenbuterol is that it is a small molecule non-hormonal drug, which can achieve a combination of therapeutic effect and comfort, and even almost no side effects for some patients. It is the first dermatological drug to enter the list of urgently needed new drugs. It can be said that the listing of clenbuterol fills the demand for the treatment of atopic dermatitis in children and adults in China, breaking the current situation of no new products in the field of topical non-hormonal anti-inflammatory for more than 10 years, which is of epoch-making significance.